Bristol-Myers Squibb (BMY) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed Sanofi (SNY) over the past year, gaining 33.8% versus a loss of 17.6%. Over five years, BMY leads with a +2.1% price change compared with -17.6% for SNY. Bristol-Myers Squibb is the larger company by market cap ($121.70 billion vs $96.40 billion), about 1.3 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 9.0x for Bristol-Myers Squibb). Sanofi offers the higher dividend yield (10.24% vs 4.21%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | SNY |
|---|---|---|
| Share price | $59.58 | $40.23 |
| Market cap | $121.70B | $96.40B |
| 1-day change | -0.20% | +0.07% |
| YTD return | +10.46% | -16.98% |
| 1-year return | +33.77% | -17.56% |
| 5-year return | +2.09% | -17.65% |
| P/E ratio (TTM) | 13.12 | 21.17 |
| Forward P/E | 9.02 | 7.45 |
| EPS (TTM) | $4.54 | $1.90 |
| Dividend yield | 4.21% | 10.24% |
| Annual dividend | $2.51 | $4.12 |
| Revenue (latest FY) | $48.19B | — |
| Revenue growth (YoY) | -0.22% | — |
| Net income (latest FY) | $7.05B | — |
| Gross margin | 71.08% | — |
| Net margin | 14.64% | — |
| 52-week high | $68.64 | $52.68 |
| 52-week low | $42.52 | $39.18 |
| Distance from 52-week high | -13.20% | -23.63% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +11.06% | +33.26% |
| Average volume | 11.30M | 2.89M |
| Shares outstanding | 2.04B | 2.40B |
| Employees | 32,500 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMY has outperformed SNY by 51.3 percentage points over the past year.
- Sanofi trades at a higher earnings multiple (21.2x vs 13.1x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.24% vs 4.21%).
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
BMY vs SNY FAQ
Which is bigger, Bristol-Myers Squibb or Sanofi?
Bristol-Myers Squibb (BMY) is larger, with a market capitalization of $121.70B compared with $96.40B for Sanofi (SNY).
Which stock has performed better over the past year, BMY or SNY?
BMY returned +33.77% over the past 12 months, compared with -17.56% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMY or SNY?
BMY has the lower trailing P/E at 13.1, versus 21.2 for SNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bristol-Myers Squibb or Sanofi?
Sanofi has the higher yield at 10.24%, compared with 4.21% for Bristol-Myers Squibb.
Are Bristol-Myers Squibb and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.